Prostate Cell News Volume 6.08 | Mar 6 2015

Elf5 Inhibits TGF-β-Driven Epithelial-Mesenchymal Transition in Prostate Cancer by Repressing SMAD3 Activation
Scientists reveal that E74-like factor 5 (Elf5) results in the failure of mesenchymal morphogenesis, upregulation of epithelial-mesenchymal transition markers, spheres formation, and migration in the presence of transforming growth factor-β (TGF-β). [Prostate] Abstract

miR-1247-5p Is Overexpressed in Castration Resistant Prostate Cancer and Targets MYCBP2
Scientists report an expression analysis of microRNA (miR)-1247-5p, miR-1249, miR-1269a, miR-1271-5p, miR-1290, miR-1291, and miR-1299. qRT-PCR was performed to validate the differential expression of miRNAs in clinical samples, and the effect of miR-1247-5p was studied in prostate cancer cell lines transiently transfected with a miR-1247-5p mimic. [Prostate] Abstract

EphB4 Localizes to the Nucleus of Prostate Cancer Cells
The EphB4 receptor tyrosine kinase is over-expressed in a variety of different epithelial cancers including prostate where it has been shown to be involved in survival, migration and angiogenesis. Researchers report that EphB4 also resides in the nucleus of prostate cancer cell lines. [Exp Cell Res] Abstract

Cancerous Inhibitor of Protein Phosphatase 2A Promotes Premature Chromosome Segregation and Aneuploidy in Prostate Cancer Cells through Association with Shugoshin
Scientists demonstrate that shugoshin and the C-terminus of cancerous inhibitor of protein phosphatase 2A interact in prostate carcinoma cell lines in a protein phosphatase 2A-dependent manner. [Tumor Biol] Abstract

Effective Photothermal Chemotherapy with Docetaxel-Loaded Gold Nanospheres in Advanced Prostate Cancer
The effect of radiolabelled multifunctional gold nanospheres (^99mTc-MGNs) on PC-3 cell apoptosis was assessed by flow cytometry, while their binding affinity to these cells was evaluated by cell binding assays. ^99mTc-MGNs showed good binding affinity to PC-3 cells, a specific recognition blocked by excess folic acid. [J Drug Target] Abstract

Isoflavone Lupiwighteone Induces Cytotoxic, Apoptotic, and Antiangiogenic Activities in DU-145 Prostate Cancer Cells
Scientists examined the antitumor activity of lupiwighteone, explored its antitumor mechanism in a human prostate carcinoma cell line, and evaluated its antiangiogenetic activity in the human umbilical vein endothelial cell line. [Anticancer Drugs] Abstract

CLINICAL RESEARCH

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 plus Docetaxel in Patients with Advanced Malignant Solid Tumors
Researchers examined the toxicity and tolerability, of pegylated arginine deiminase (ADI-PEG 20) in combination with docetaxel in patients with advanced solid malignancies. [Clin Cancer Res] Abstract

A Randomized Phase II Trial Comparing Docetaxel plus Prednisone with Docetaxel plus Prednisone plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer
Scientists compared the combination therapy of docetaxel plus prednisone plus cyclophosphamide with the standard therapy of docetaxel plus prednisone. [Chemotherapy] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC^®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
Bavarian Nordic and Bristol-Myers Squibb Company announced an agreement that provides Bristol-Myers Squibb an exclusive option to license and commercialize PROSTVAC^®, Bavarian Nordic’s investigational Phase III prostate-specific antigen-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. [Bristol-Myers Squibb Company] Press Release

VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics^® Technology
VolitionRx Limited announced that it has initiated a pilot study to assess the feasibility of VolitionRx’s proprietary NuQ^® assays in detecting prostate cancer. [VolitionRx Limited] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Prostate Cancer (University of Sydney)

PhD Studentship – Prostate Cancer (University of Hull)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Research – Scientist Metabolic Adaptation in Treatment Resistant Prostate Cancer (Cancer Research UK Beatson Institute in Glasgow)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.